Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Interest Expenses (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Interest Expenses data on record, last reported at $725000.0 in Q3 2025.

  • For Q3 2025, Interest Expenses fell 45.77% year-over-year to $725000.0; the TTM value through Sep 2025 reached $3.7 million, down 29.5%, while the annual FY2024 figure was $5.0 million, 1.02% down from the prior year.
  • Interest Expenses reached $725000.0 in Q3 2025 per RANI's latest filing, down from $876000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.3 million in Q3 2024 and bottomed at -$1000.0 in Q4 2021.
  • Average Interest Expenses over 5 years is $835117.6, with a median of $943000.0 recorded in 2025.
  • Peak YoY movement for Interest Expenses: crashed 101.72% in 2021, then skyrocketed 72000.0% in 2022.
  • A 5-year view of Interest Expenses shows it stood at -$1000.0 in 2021, then surged by 72000.0% to $719000.0 in 2022, then surged by 80.25% to $1.3 million in 2023, then dropped by 13.27% to $1.1 million in 2024, then tumbled by 35.5% to $725000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $725000.0 in Q3 2025, $876000.0 in Q2 2025, and $943000.0 in Q1 2025.